Anti-TL1A/anti-TNF-alpha bispecific antigen binding proteins and uses thereof
The present invention concerns antigen binding proteins that bind TLIA, including bispecific antigen binding pro -teins (e.g., antibodies) to TLIA and TNF-a. Such bispecific antibodies can be in a tetrameric immunoglobulin format, in which one heavy chain-light chain pair of the antibody is directed...
Saved in:
Main Authors | , , , , |
---|---|
Format | Patent |
Language | English |
Published |
11.04.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present invention concerns antigen binding proteins that bind TLIA, including bispecific antigen binding pro -teins (e.g., antibodies) to TLIA and TNF-a. Such bispecific antibodies can be in a tetrameric immunoglobulin format, in which one heavy chain-light chain pair of the antibody is directed to TLIA and the other to TNF-a. The bispecific antigen binding proteins may also be comprised in an IgG-scFv fusion, in which a conventional tetrameric antibody directed to one antigen is fused to a pair of single chain Fv units directed to the other. The bispecific antigen binding protein may also be comprised in an IgG-Fab fusion, in which a Fab molecule that binds to one antigen is fused to each heavy chain of a conventional tetrameric antibody directed to the other antigen. The invention further relates to uses of the anti-TL lA binding proteins and anti-TL 1 A/ anti-TNF -alpha antigen binding proteins, and pharmaceutical formulations thereof. |
---|---|
Bibliography: | Application Number: AU20240200534 |